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Background: Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by the presence of anti-
mitocondrial autoantibodies (AMA) which has an essential role also for diagnosis. In addition, also some anti-
nuclear antibodies (ANA) have been shown to be highly specific PBC. The purpose of this study was to assess the
prevalence of PBC among the adults referring hospital for annual health check-up in Southern China by screening
sera for PBC-specific autoantibodies.
Methods: AMA and ANA were screened in 8,126 adults (mean age 44 ± 15 years, 48% females) by indirect
immunofluorenscence (IIF). Positive sera were tested by ELISA/immunoblotting for AMA-M2, anti-sp100 and anti-
gp210. A diagnosis of PBC was re-assessed six months after the initial testing.
Results: Out of 8,126 individuals 35 were positive for AMA and 79 positive for ANA. Nineteen, 4, and 3 of the
subjects positive for AMA and/or ANA showed reactivity for AMA-M2, anti-sp100 or gp210, respectively, further
tested with ELISA/immunoblotting. Fourteen in the 39 individuals positive for AMA at IIF, AMA-M2, anti-gp210, or
anti-sp100 had abnormal cholestatic liver functional indices. One definite and 3 probable PBC diagnosis could be
made in 4 cases including 3 females and 1 male after half a year.
Conclusions: We found a point prevalence rate of PBC among Southern Chinese adults attending for yearly health
check-up of 492 cases per million (95% CI, 128 to 1,093) and 1,558 cases per million (95% CI, 294 to 3,815) for
women over 40, a finding similar to prevalence reported in other geographical areas.
Background
Primary biliary cirrhosis (PBC) is an autoimmune liver
disease leading to progressive destruction of small intra-
hepatic bile ducts, development of cirrhosis, and liver
failure [1]. PBC affects predominantly women over mid-
dle-age [2]. It has been reported that PBC is more pre-
valent in some geographic areas such as Northern
Europe and Northern America but much less common
in Eastern Asia, Africa, and Australia [3-6]. However, it
is worth noting that a rising frequency in many areas
may be due to a more widespread awareness of this dis-
ease among physicians. Case series of Chinese patients
with PBC have been reported from Taiwan, Hong Kong,
Singapore and, more recently, also from Mainland
China [6-11], with a number of Chinese patients with
PBC apparently to be increasing in recent years. How-
ever, no epidemiological data have accompanied these
reports.
PBC is serologically characterized by the presence of
anti-mitochondrial antibodies (AMA), which are reactive
mainly with E2 subunits of mitochondrial multi-enzyme
complexes, the 2-oxo-acid dehydrogenase complexes
comprising pyruvate dehydrogenase complex (PDC),
branched chain 2-oxo-acid dehydrogenase complex
(BCOADC) and 2-oxo-glutarate dehydrogenase complex
(OGDC) [12]. These specific AMA are called AMA-M2
and are detectable in up to 95% of the patients [13,14].
In addition to AMA, two distinct anti-nuclear antibodies
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escence (IIF), the multiple nuclear dot (MND) and rim-
like (RL) patterns, for which the reactants are sp100 and
the glycoprotein gp210 respectively [15,16].
The aim of this study was to investigate the preva-
lence of PBC among adults referring for annual health
check-up by screening PBC-specific autoantibodies.
Methods
Subjects
A total of 8,126 citizens of Guangzhou, Southern China,
aged from 18 to 83 years, with a median age of 44 ± 15
years, were consecutively enrolled in the study. 4,248
(52%) were males (median age of 46 ± 15 years), 3,878
(48%) were females (median age 41 ± 14 years), and
1,926 (24%) were aged over 40 years. They underwent a
yearly health check-up at the Liuhuaqiao Hospital from
June to September 2006, including a physical examina-
tion, routine blood tests, abdominal ultrasonography,
chest X ray, electrocardiogram, and serum markers of
hepatitis B (HBsAg). The male to female ratio in the
current study (1.1) reflects the general sex distribution
in Guangzhou (1.0) investigated at the end of 2005
http://www.civic-exchange.org/eng/upload/files/
200806_AirQualityPublicHealth.pdf.
This study was in compliance with the Helsinki
Declaration http://www.wma.net/e/policy/b3.htm and
was approved by the regional ethical committee of the
Guangdong province, China. All subjects signed an
informed consent to be enrolled and all data were dealt
with in an anonymous way.
Screening of AMA and ANA
Figure 1 shows the experimental procedure of the study.
Pools of sera from 6 subjects were prepared from the
8,126 available sera, and each pool was tested for AMA
and ANA reactivity by IIF using HEp-2 cells as substrate
according to the instructions of the manufacturer (Euro-
immun, Luebeck, Germany). HEp-2 cell lines were used
for screening of both ANA and AMA although the pre-
ferable substrate is that of combination of rodent tissues
[17,18]. Sera from each positive pool were then indivi-
dually tested with the same approach in order to iden-
tify each individual positive serum sample. A coarse
speckled cytoplasmic staining of mitochondria HEp-2
cells was read as AMA positive, but AMA was then
further confirmed by IIF on rat kidney tissues
(Euroimmun).
Detection of AMA-M2, anti-gp210 and anti-sp100
Sera positive for AMA and/or ANA by IIF were further
tested for AMA-M2, anti-gp210 and anti-sp100. AMA-
M2 in serum samples diluted 1:100 were determined
using ELISA kits with wells coated with recombinant
fusion protein containing the immunodominant epitopes
of human PDC-E2, BCOADC-E2 and OGDC-E2
(Fuchunzhongnan Biotech, Shanghai, China). Anti-sp100
and anti-gp210 were detected at a dilution of 1:100 by
an immunoblotting assay with recombinant sp100 and
gp210 proteins (IMTEC, Berlin, Germany).
Laboratory indices
The routine diagnostic laboratory indices included liver
function such as serum total protein, albumin, alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), total cholesterol, triglyceride, and immunoassays
for hepatitis B virus (HBV) infection (HBsAg, anti-HBs,
HBeAg, anti-HBe and anti-HBc). Sera positive for PBC-
specific autoantibodies were additionally tested for anti-
bodies against other hepatitis viruses (HAV, HCV and
HEV), serum immunoglobulins (Ig), total bilirubin
(TBil), alkaline phosphatase (AP), and gamma-glutamyl
transpeptidase (g-GT).
Diagnosis of PBC
All subjects positive for at least one of the PBC-specific
antibodies and with abnormal results for liver function
tests were advised to visit hepatologists for further
Figure 1 Experimental procedure of screening autoantibodies
and diagnosis.
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months. A diagnosis of PBC was made according to cri-
teria recommended by the European Association for the
study of the Liver (EASL) [19]: unexplained elevation of
ALP and presence of AMA (≥ 1:40) and/or AMA-M2.
Statistical analysis
SPSS13.0 software was applied to calculate 95% confi-
dence intervals (CI) for frequencies of autoantibodies
a n dt h ep o i n tp r e v a l e n c er a t eo fP B C .c
2 test was used
to compare categorical variables. Two-tailed P values of
less than 0.05 were considered to be statistically
significant.
Results
AMA and ANA frequencies
Out of the 8,126 subjects, 104 were tested positive for
A M Aa n d / o rA N Aa tI I F .B o t hA N Aa n dA M Aw e r e
tested by HEp-2 cell lines for financial constraints and
because this approach allowed to obtain information on
ANA patterns. Among them, 35 (0.43%, 95% CI: 0.30%-
0.58%) were positive for AMA, 15 males and 20 females,
mean age, 55 ± 15 (range, 23-83 years); 79 (0.97%)
tested ANA positive and the frequencies of different
ANA patterns were shown in table 1. A speckled pattern
was the most common (44.3%); MND and RL patterns
were observed in 11 (13.9%) and 4 subjects (5.1%),
respectively. Sera from 10 ANA-positive individuals
were concurrently AMA positive.
AMA-M2, anti-sp100 and anti-gp210 frequencies
Twenty-two of the 104 sera (22%) that tested positive
for AMA and/or ANA by IIF contained autoantibodies
directed against specific mitochondrial and/or nuclear
antigens as shown in table 2. In particular, 19, 4, and 3
o ft h e s e1 0 4s e r aw e r ef o u n dt ob ep o s i t i v ef o ra n t i -
AMA-M2, anti-sp100 and anti-gp210, respectively. Dis-
tribution of PBC-specific autoantibodies including
AMA-M2, anti-sp100 and anti-gp210 in male vs. female
at different ages was shown in figure 2. None of specific
autoantibodies (anti-AMA-M2, anti-sp100 or anti-
gp210) was detected in the individuals at the age of
18~29. These autoantibodies occurred seldom in adults
before age of 40 and the positive rates did not increased
with age (P > 0.05). Although the PBC-specific autoanti-
bodies prevalence in female over age of 40 was 0.62%
and 1.32% for women over 60, several folds of that
found among males of similar age, there was no statisti-
cal difference between female and male at all ages
(P > 0.05).
Clinical characteristics of subjects with PBC-specific
antibodies
There was 17 individuals AMA positive at IIF in whom
none of M2, anti-sp100 or anti-gp210 was detected.
Overall, 39 of the 8,126 sera (0.48%, 95% CI: 0.34%-
0.64%) were tested positive for AMA at IIF, AMA-M2,
anti-gp210, or anti-sp100, that is all the known PBC-
specific serum immunoreactivities [2,15]. Fourteen of
these 39 individuals (8 of 14 w e r ef e m a l e s )h a da tl e a s t
one abnormal test of liver function. None showed signs
of current infection with a hepatitis virus. All 14 sub-
jects with abnormal tests of liver function were
contacted for further clinical evaluation, but only one, a
Table 1 Indirect immunofluorescence patterns of 79
subjects with anti-nuclear antibodies (ANA) on HEp-2
cells.




Multiple nuclear dots 11 13.9
Homogeneous 7 8.9
Rim-like 4 5.1
Table 2 Indirect immunofluorescence (IIF) patterns
according to specific immunoreactivities (AMA-M2, anti-
sp100 and anti-gp210) in the 104 sera positive for AMA
and/or ANA.




MND 3 1 1 0 1 0
Rim-like 1 0 0 1 0 0
AMA 15 12 0 1 1 1
AMA+MND 2 2 0 0 0 0
AMA
+Speckled
11 0 0 0 0
Total 22 16 1 2 2 1
Note. Abbreviations are same as that in the text.
Figure 2 Distribution of PBC-specific autoantibodies in male
and female at different ages. None of PBC-specific autoantibodies
(AMA-M2, anti-sp100 or anti-gp210) was detected in the individuals
at the age of 18~29. There was no significant difference in the
frequency of PBC-specific autoantibodies between male and female
at all ages (P > 0.05).
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immunoglobulins, total bilirubin, AP, and g-GT, under-
went ERCP and liver biopsy. ERCP did not disclose bili-
ary tract abnormalities, and liver biopsy showed
periportal hepatitis and bile duct proliferation indicative
of a histological stage II PBC [20]. Another three cases
without any related clinical signs, 2 females and one
male aged 41, 64, 47 respectively, maintained abnormal
liver functional indices after six months and also fulfilled
the diagnostic criteria of PBC proposed by EASL.
Discussion and conclusions
The first patient to be recorded with PBC in Mainland
China was reported in 1958 and only an additional 48
cases were later on reported from 1980 to 2000 [21].
Although there have been an increasing number of
reported diagnoses, PBC is still thought to be very rare
in Asian populations. Moreover, there is a lack of solid
epidemiological information relevant to this issue [3].
Therefore, we took advantage of annual health check-up
data and designed a study to estimate the prevalence of
PBC in the adult population of a defined area of South-
ern China by screening for all the known PBC-specific
serum autoantibodies [15].
Four individuals were diagnosed as PBC, 3 females
and 1 male, among 8,126 adults (over age 18) resident
in the Southern Chinese city of Guangzhou who
attended for an annual health check-up; the rate of
hepatitis B virus in this population was 8.1%. The point
prevalence rate of PBC was 492 cases per million (95%
CI: 128 to 1,093), among the highest reported in other
geographical regions [5,22-26]. By considering the risk
of PBC for women over 40 years, i.e. a “high risk
group”, a prevalence of 1,558 cases per million (95% CI:
294 to 3,815) was observed.
Unfortunately, we could not confirm the diagnosis of
PBC by means of liver biopsy in all the subjects with
cholestasis and the presence of PBC-specific autoantibo-
dies. But the serum autoantibodies we determined are
highly specific for PBC [15], which allowed us to screen
adults in a relatively natural distribution of the general
population, thus providing a fair estimate of the real
prevalence of PBC in Mainland China.
The prevalence of PBC found in our study is similar
to that reported in an early evaluation from Italy, in
which diagnosis was based on ultrasound scanning, ele-
vated AP and presence of AMA [27], but much lower
than the estimated prevalence of PBC for middle-aged
women in Japan [28]. However, it is to note that in this
latter study the screening comprised only increase in
serum g-GT levels among 4,048 asymptomatic women
attending for an annual health check-up. It is evident
that prevalence obtained from laboratory parameters are
higher than prevalence derived from studies using a
physician survey and review of hospital records [29-33].
The reason may be that laboratory methods can identify
asymptomatic cases that would be overlooked by case-
finding; for instance, the four PBC patients identified in
our study including the patient who already developed
symptoms had never encountered a hepatologist. Over-
all, the variation in PBC prevalence among different stu-
dies may be attributable to differences in study
populations and periods and the methods of case ascer-
tainment [5].
Jiang and colleagues identified 3 (0.06%) PBC cases
from 5,011 adults from eastern China [34]. Lately, 38
PBC cases were reported in Singapore, a small Asian
city-state with population of 4 million and ethnic distri-
bution of 76% Chinese [11]. Based on the current and
early findings, the prevalence of PBC in Asia, especially
in Mainland China, is not as rare as might be expected,
being comparable with high prevalence sites in Northern
Europe and the United States of America [5].
In areas like Mainland China where there is still lack
of registry system for healthcare and PBC is not well
recognized by clinical doctors the need of data on dis-
ease prevalence and incidence is crucial. We are now
reporting data from a screening of PBC starting from
combination of PBC specific autoantibodies in adults at
random with age and sex in a relatively natural distribu-
tion. We are aware that our cross-sectional observa-
tional study has a number of limitations, also because
allowed us to identify only a small absolute number of
cases. Theoretically, a population-based study is the best
study design to define the prevalence of a disease, and
efforts have to be done to accomplish such studies in
the near future.
Intriguingly, the current study confirms the observa-
tion of a nearly equal male to female ratio found in
large-scale screening studies, as we have recently high-
lighted [35]. On the contrary, studies based on
case-finding methods reported a strong female prepon-
derance, possibly because they account only for already
diagnosed cases [35]. Although the reasons for this dis-
crepancies remain unknown, clearly rely to the different
study designed used.
In summary, our data suggest that PBC is not as rare
as expected before with the point prevalence rate of
PBC in Chinese which is quite comparable to that
reported in other geographical areas.
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